Last reviewed · How we verify
Erlotinib plus sulindac
At a glance
| Generic name | Erlotinib plus sulindac |
|---|---|
| Also known as | Tarceva |
| Sponsor | University of Pittsburgh |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erlotinib plus sulindac CI brief — competitive landscape report
- Erlotinib plus sulindac updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI